Grant Bishop

Tuesday, 10 November 2026 · Markets closed · Edition 20

Doximity

DOCS

Doximity sells software for doctors and pharmacies, including telehealth tools and drug-prescribing platforms. We follow it because it may gain indirectly as AI spreads through the healthcare businesses it serves.

Checked against the company's own business description in its latest annual filing. · entry updated 2026-10-19
Ticker
DOCS
Exchange
—
Price
—
Change
—
As of
—
Market cap
—
EV/EBIT
—
P/E NTM
—
FCF yield
—
Net debt/EBITDA
—
Next earnings
—

Last refreshed from 10-Q filed (EDGAR)

Follow · Add to calendar · Daily window

The living report

Bears on our standing view that AI's economy-wide productivity lift does not arrive before 2028. It is proved wrong if productivity jumps much sooner than we expect, or adoption stops spreading.

last revised 19 Oct 2026 · next scheduled disclosure not yet announced
The full report

Members: queues this company for a report on a coming night.

The market record

Free during the preview. Each figure shows only where two independent data providers, Massive and Yahoo, agree on it to the cent; a figure they do not agree on is left out. Dated, not live. It describes; it does not recommend.

Last close$32.51
close of 6 Nov 2026 · Massive and Yahoo agree
The day's range$29.80 – $32.62
6 Nov 2026 · both providers agree
52-week range$17.15 – $58.24
intraday low 14 May 2026 · intraday high 7 Nov 2025 · 251 sessions to 6 Nov 2026 · both providers agree
$

Enter any price. The page shows the multiple on the forward estimate on file and where that price sits in the 52-week range. It computes; it does not recommend.

Filings

Newest first, from EDGAR. Where a piece read a filing, one line of what it said.

5 Nov 202610-Q · period ending 30 Sep 2026
5 Nov 20268-K · period ending 5 Nov 2026
2 Sep 20268-K · period ending 27 Aug 2026
6 Aug 202610-Q · period ending 30 Jun 2026
6 Aug 20268-K · period ending 6 Aug 2026
19 May 202610-K · period ending 31 Mar 2026
13 May 20268-K · period ending 13 May 2026
17 Apr 20268-K · period ending 13 Apr 2026
5 Feb 202610-Q · period ending 31 Dec 2025
5 Feb 20268-K · period ending 3 Feb 2026
30 Dec 20258-K · period ending 24 Dec 2025
6 Nov 202510-Q · period ending 30 Sep 2025
6 Nov 20258-K · period ending 6 Nov 2025
2 Sep 20258-K · period ending 28 Aug 2025
15 Aug 20258-K · period ending 13 Aug 2025
7 Aug 202510-Q · period ending 30 Jun 2025
7 Aug 20258-K · period ending 7 Aug 2025
13 Jun 20258-K · period ending 10 Jun 2025
20 May 202510-K · period ending 31 Mar 2025
15 May 20258-K · period ending 15 May 2025
6 Feb 202510-Q · period ending 31 Dec 2024
6 Feb 20258-K · period ending 6 Feb 2025
7 Nov 202410-Q · period ending 30 Sep 2024
7 Nov 20248-K · period ending 7 Nov 2024

Where it sits in the frame

Reports next

not yet announced

Latest disclosed

10-Q · filed 2026-08-06 · period ending 2026-06-30

Read the filing

Machine-readable

/index/DOCS.json

What it has disclosed

Newest first. Every figure traces to a filing; "Show sources" shows which.

—No figure from this company appears in a committed piece yet.

Mentioned in

Every piece that names this company, newest first: what it said, and the standing view it bore on. Written when the piece is committed; never edited, never removed.

—No piece names this company yet.

Same question

Other companies under Who may gain as AI spreads through other businesses?

This entry

19 Oct 2026Entry rewritten in plain words: what the company sells, and why we follow it.
12 Oct 2026Verified against the 10-Q filed 2026-08-06 at launch.

Prices on this page are dated market records, shown free during the preview, each confirmed by two independent data providers. None is a recommendation.

Follow Doximity. The weekly piece, and a note when a filing moves it.

Record

Written according to the Grant Bishop standard — machine-researched, machine-checked, human-judged; then read and committed by the publisher. Every number traces to a filing or a dated market record; every claim carries a date and what would prove it wrong.

Verification
multi-source verified, machine-drafted, human-gated
As of
2026-08-06
Position disclosure
The publisher holds index-level U.S. equity exposure and no direct position in any single name discussed.
Not advice
General commentary for a general audience. Not advice for your situation.
Sources (12)